Biodistribution of Radiolabelled Antibody in Small Cell Lung Cancer Patients
Author Information
Author(s): J.A. Ledermann, N.J. Marston, R.A. Stahel, R. Waibel, J.R. Buscombe, P.J. Eli
Primary Institution: University College London Medical School
Hypothesis
The biodistribution of radiolabelled SWA 11 in humans differs from animal models and may not be suitable for targeting therapy in small cell lung cancer.
Conclusion
The study found that the biodistribution of radiolabelled SWA 11 in humans is not effective for targeting small cell lung cancer due to high uptake in bone marrow and granulocytes.
Supporting Evidence
- Radiolabelled SWA 11 was injected into five patients with small cell lung cancer.
- Only two out of five patients showed detectable tumors using gamma camera imaging.
- Most of the radioactivity was found in the bone marrow, not the tumors.
Takeaway
Doctors tested a special antibody in five patients with lung cancer to see where it goes in the body, but it mostly went to the bones instead of the tumors.
Methodology
Five patients with small cell lung cancer were injected with radiolabelled SWA 11, and their biodistribution was studied using gamma camera imaging.
Limitations
The antibody's biodistribution in humans was different from animal models, indicating potential limitations in using animal studies to predict human outcomes.
Participant Demographics
Patients included two with newly diagnosed, one relapsed, and two persistent small cell lung cancer.
Want to read the original?
Access the complete publication on the publisher's website